Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 133

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function

Plotegher, N., Berti, G., Ferrari, E., Tessari, I., Zanetti, M., Lunelli, L., Greggio, E., Bisaglia, M., Veronesi, M., Girotto, S., Dalla Serra, M., Perego, C., Casella, L., Bubacco, L.·2017·Scientific Reports

Abstract

Parkinson’s disease is a neurodegenerative disorder characterized by the death of dopaminergic neurons and by accumulation of alpha-synuclein (aS) aggregates in the surviving neurons. The dopamine catabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL) is a highly reactive and toxic molecule that leads to aS oligomerization by covalent modifications to lysine residues. Here we show that DOPAL-induced aS oligomer formation in neurons is associated with damage of synaptic vesicles, and with alterations in the synaptic vesicles pools. To investigate the molecular mechanism that leads to synaptic impairment, we first aimed to characterize the biochemical and biophysical properties of the aS-DOPAL oligomers; heterogeneous ensembles of macromolecules able to permeabilise cholesterol-containing lipid membranes. aS-DOPAL oligomers can induce dopamine leak in an in vitro model of synaptic vesicles and in cellular models. The dopamine released, after conversion to DOPAL in the cytoplasm, could trigger a noxious cycle that further fuels the formation of aS-DOPAL oligomers, inducing neurodegeneration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep40699

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 49

  1. German, D. C., Manaye, K., Smith, W. K., Woodward, D. J. & Saper, C. B. Midbrain dopaminergic cell loss in Parkinson’s disease: computer visualization. Ann Neurol 26, 507–514 (1989). · DOI · Paper page
  2. Bisaglia, M., Greggio, E., Beltramini, M. & Bubacco, L. Dysfunction of dopamine homeostasis: Clues in the hunt for novel Parkinson’s disease therapies. FASEB J 27, 2101–2110 (2013). · DOI
  3. Goldstein, D. S., Kopin, I. J. & Sharabi, Y. Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol Ther 1110 (2014). · DOI · Paper page
  4. Galvin, J. E. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol 112, 115–126 (2006). · DOI
  5. Goldstein, D. S. et al. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson’s disease. J Neurochem 126, 591–603 (2013). · DOI · Paper page
  6. Goldstein, D. S. et al. Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol 18, 703–710 (2011). · DOI
  7. Grünblatt, E. et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111, 1543–1573 (2004). · DOI · Paper page
  8. Doorn, J. a., Florang, V. R., Schamp, J. H. & Vanle, B. C. Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons. Park Relat Disord 20, S73–S75 (2014). · DOI
  9. Fitzmaurice, A. G. et al. Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc Natl Acad Sci USA 110, 636–41 (2013). · DOI · Paper page
  10. Fitzmaurice, A. G., Rhodes, S. L., Cockburn, M., Ritz, B. & Bronstein, J. M. Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease. Neurology 82, 419–426 (2014). · DOI
  11. Legros, H., Dingeval, M. G., Janin, F., Costentin, J. & Bonnet, J. J. Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: Relationships with 3,4-dihydroxyphenylacetaldehyde formation. Neurotoxicology 25, 365–375 (2004). · doi:10.1016/s0161-813x(03)00148-7
  12. Wey, M. C. Y. et al. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: Implications for parkinson’s disease. PLoS One 7 (2012). · DOI · Paper page
  13. Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839–840 (1997). · DOI · Paper page
  14. Kasten, M. & Klein, C. The many faces of alpha-synuclein mutations. Mov Disord 28, 697–701 (2013). · DOI
  15. Nemani, V. M. et al. Article Increased Expression of a -Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis. Neuron 65, 66–79 (2010). · DOI · Paper page
  16. Scott, D. & Roy, S. -Synuclein Inhibits Intersynaptic Vesicle Mobility and Maintains Recycling-Pool Homeostasis. J Neurosci 32, 10129–10135 (2012). · DOI · Paper page
  17. Burré, J. et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro . Science 329, 1663–1667 (2010). · DOI · Paper page
  18. Outeiro, T. F. et al. Dopamine-Induced Conformational Changes in Alpha- Synuclein. PLoS One 4, 1–11 (2009). · DOI
  19. Nakamura, K. Alpha-Synuclein and Mitochondria: Partners in Crime? Neurotherapeutics 10, 391–399 (2013). · DOI
  20. Ebrahimi-Fakhari, D., Wahlster, L. & McLean, P. J. Protein degradation pathways in Parkinson’s disease: Curse or blessing. Acta Neuropathol 124, 153–172 (2012). · DOI · Paper page
  21. Auluck, P. K., Caraveo, G. & Lindquist, S. α-Synuclein: membrane interactions and toxicity in Parkinson’s disease. Annu Rev Cell Dev Biol 26, 211–233 (2010). · DOI · Paper page
  22. Plotegher, N., Greggio, E., Bisaglia, M. & Bubacco, L. Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicity. Q Rev Biophys 1, 1–48 (2014). · DOI
  23. Wilhelm, B. G. et al. Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science (80-) 344, 1023–1028 (2014). · DOI · Paper page
  24. Theillet, F.-X. et al. Structural disorder of monomeric α-synuclein persists in mammalian cells. Nature 530, 45–50 (2016). · DOI · Paper page
  25. Plotegher, N. & Bubacco, L. Lysines, Achilles’ heel in alpha-synuclein conversion to a deadly neuronal endotoxin. Ageing Res Rev 26, 62–71 (2016). · DOI
  26. Burke, W. J. et al. Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 115, 193–203 (2008). · DOI · Paper page
  27. Goldstein, D. S. et al. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: Relevance to the pathogenesis of Parkinson’s disease. J Neurochem 123, 932–943 (2012). · DOI
  28. Jinsmaa, Y. et al. Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein. Neurosci Lett 569, 27–32 (2014). · DOI
  29. Follmer, C. et al. Oligomerization and Membrane-Binding Properties of Covalent Adducts Formed by the Interaction of Alpha-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). J Biol Chem 290, jbc.M115.686584 (2015). · DOI · Paper page
  30. Daniele, F., Di Cairano, E. S., Moretti, S., Piccoli, G. & Perego, C. TIRFM and pH-sensitive GFP-probes to Evaluate Neurotransmitter Vesicle Dynamics in SH-SY5Y Neuroblastoma Cells: Cell Imaging and Data Analysis. J Vis Exp e52267, doi: 10.3791/52267 (2015). · doi:10.3791/52267
  31. Belluzzi, E. et al. LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate. Mol Neurodegener 11, 1 (2016). · DOI · Paper page
  32. Piccoli, G. et al. LRRK2 Controls Synaptic Vesicle Storage and Mobilization within the Recycling Pool. J Neurosci 31, 2225–2237 (2011). · DOI · Paper page
  33. Rees, J. N., Florang, V. R., Eckert, L. L. & Doorn, J. a. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chem Res Toxicol 22, 1256–1263 (2009). · DOI
  34. Lashuel, H. a. et al. Α-Synuclein, Especially the Parkinson’S Disease-Associated Mutants, Forms Pore-Like Annular and Tubular Protofibrils. J Mol Biol 322, 1089–1102 (2002). · DOI · Paper page
  35. Kim, H.-Y. et al. Structural Properties of Pore-Forming Oligomers of alpha -Synuclein. J- Amer Chem Soc 131, 17482–17489 (2009). · DOI · Paper page
  36. Quist, A. et al. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 102, 10427–10432 (2005). · DOI · Paper page
  37. Chen, S. W. et al. Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. Proc Natl Acad Sci USA 112, E1994–2003 (2015).
  38. Plotegher, N. et al. The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity. Hum Mol Genet 1–38, doi: 10.1093/hmg/ddu275 (2014). · DOI
  39. Stöckl, M. T., Zijlstra, N. & Subramaniam, V. α-Synuclein Oligomers: an Amyloid Pore? - Insights into Mechanisms of α-Synuclein Oligomer-Lipid Interactions. Mol Neurobiol 1–9, doi: 10.1007/s12035-012-8331-4 (2012). · DOI
  40. Tosatto, L. et al. Alpha-synuclein pore forming activity upon membrane association. Biochim Biophys Acta - Biomembr 1818, 2876–2883 (2012). · DOI
  41. De Franceschi, G. et al. Structural and morphological characterization of aggregated species of α-synuclein induced by docosahexaenoic acid. J Biol Chem 286, 22262–22274 (2011). · DOI
  42. Van Maarschalkerweerd, A., Vetri, V. & Vestergaard, B. Cholesterol facilitates interactions between α-synuclein oligomers and charge-neutral membranes. FEBS Lett 589, 2661–2667 (2015). · DOI
  43. Jao, C. C., Der-Sarkissian, A., Chen, J. & Langen, R. Structure of membrane-bound α-synuclein studied by site-directed spin labeling. Proc Natl Acad Sci USA 101, 8331–8336 (2004). · DOI · Paper page
  44. Jao, C. C., Hegde, B. G., Chen, J., Haworth, I. S. & Langen, R. Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. Proc Natl Acad Sci USA 105, 19666–19671 (2008). · DOI · Paper page
  45. Tessari, I. et al. The reaction of α-synuclein with tyrosinase: Possible implications for parkinson disease. J Biol Chem 283, 16808–16817 (2008). · DOI
  46. Robbins, J. H. Preparation and Properties of p-Hydroxyphenylacetaldehyde and 3-Methoxy-4-Hydroxyphenylacetaldehyde. Arch Biochem Biophys 114, 576–584 (1966). · doi:10.1016/0003-9861(66)90382-1
  47. Dalla Serra, M. & Menestrina, G. Characterization of molecular properties of pore-forming toxins with planar lipid bilayers. Methods Mol Biol 145, 171–88 (2000).
  48. Czajkowsky, D. M., Hotze, E. M., Shao, Z. & Tweten, R. K. Vertical collapse of a cytolysin prepore moves its transmembrane beta-hairpins to the membrane. EMBO J 23, 3206–15 (2004). · doi:10.1038/sj.emboj.7600350
  49. Nikonenko, A. G. & Skibo, G. G. Technique to quantify local clustering of synaptic vesicles using single section data. Microsc Res Tech 65, 287–291 (2004). · DOI

Cited by

See all 133

Metadata

Authors
Plotegher, N., Berti, G., Ferrari, E., Tessari, I., Zanetti, M., Lunelli, L., Greggio, E., Bisaglia, M., Veronesi, M., Girotto, S., Dalla Serra, M., Perego, C., Casella, L., & Bubacco, L.
Venue
Scientific Reports
Published
2017-01-13
Volume
7
Issue
1
ISSN
2045-2322
Cited by
133
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. https://app.cochat.ai/papers/10.1038/srep40699
The paper
Plotegher, N., Berti, G., Ferrari, E., Tessari, I., Zanetti, M., Lunelli, L., Greggio, E., Bisaglia, M., Veronesi, M., Girotto, S., Dalla Serra, M., Perego, C., Casella, L., & Bubacco, L. (2017). DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Scientific Reports. https://doi.org/10.1038/srep40699

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.